I am mindful of how life altering a diagnosis of cancer can be, not just for the patient, but all the loved ones in their life as well. Patients and families rightly deserve, and will always get the very best of us in intelligence and compassion, along with access to state of the art treatment which is continually improving long-term outcomes.
Work and Credentials:
Primary Location
Position
Medical Oncologist
Board Certification
Medical Oncology, Hematology, and Internal Medicine
Fellowship
Northwestern University Feinberg School of Medicine, Medical Oncology and Hematology
Internship
University of Michigan Health System
Residency
University of Michigan Health System
Medical School
Rutgers Robert Wood Johnson Medical School
College
Rutgers University
Special Interests
Malignant hematology (leukemia, lymphoma, myeloma), lung cancer, breast cancer & Clinical Trials
Mitul Gandhi, M.D. attended Rutgers University where he graduated Magna Cum Laude with a Bachelor of Arts in Molecular Biology and Biochemistry. He earned his medical degree from Rutgers Robert Wood Johnson Medical School where he received the Robert Wood Johnson Foundation Research Award among other honors. Dr. Gandhi then completed his residency and internship in Internal Medicine at University of Michigan Health System.
Dr. Gandhi joins Virginia Cancer Specialists after serving as Chief Fellow in the Medical Oncology and Hematology Fellowship program at Northwestern University Feinberg School of Medicine. During his time at Northwestern, Dr. Gandhi actively participated in clinical research, with a focus in high risk lymphoma. He has presented at major national meetings, won the American Society of Hematology’s Abstract Achievement Award in 2013, and has several publications including a recent article in Blood on double hit lymphomas. Dr. Gandhi is currently an Associate Member of both the American Society of Hematology and the American Society of Clinical Oncology.
In his spare time, Dr. Gandhi enjoys traveling with his wife, reading and writing, and spending time with family and friends.
Physician Video:
'
Practice Blog
October 11, 2021
Virginia Cancer Specialists Participating in National Pilot Project to Increase Diversity in Cancer Treatment Trials
Read MoreOctober 4, 2021
Virginia Cancer Specialists Opens New Office in Fauquier -- Expanding Access to Cancer Care, Research and Clinical Trials
Read MoreMore Posts by Mitul Gandhi, MD
March 2, 2021
Mitul Gandhi, MD - Myeloma: Symptoms, Treatment, and the Role of Clinical Trials Event - March 25 2021
Read MoreJune 15, 2020
Dr. Mitul Gandhi, highlights key abstracts from the #ASCO20 Virtual Scientific Program that aim to improve outcomes for patients with multiple myeloma
Read MoreMay 20, 2020
Practice Message Covid19 and Cancer: Cancer Doesn't Stop in a Pandemic
Read MorePhysician Publications
December 6, 2020
Safety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma
Read MoreDecember 5, 2020
NHL Patients and Nurses in the US Prefer Subcutaneous Rituximab Injection Versus Intravenous Rituximab Infusion: A Real-World Study
Read MoreFebruary 15, 2016
Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Read MoreMore Publications by Mitul Gandhi, MD
May 1, 2014
Pancreatitis in patients treated with Brentuximab Vedotin: A previously unrecognized serious adverse
Read MoreApril 22, 2014
Predicting benefit from imatinib. Are we close? Leukemia and Lymphoma.
Read MoreFebruary 13, 2014
Targeted treatment of head and neck squamous cell carcinoma: potential of lapatinib.
Read MoreNovember 15, 2013
Impact of Induction Regimen and Consolidative Stem Cell Transplantation in Double Hit Lymphoma (DHL)
Read MoreJanuary 7, 2013
Association of implantable defibrillator therapy risk with body mass index in systolic heart failure
Read MoreJanuary 1, 2013
Brentuximab Vedotin in Patients with Relapsed HIV-Related Lymphoma
Read MoreClinical Trials (18)
Clinical Trial 22041
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)
Clinical Trial 21287
A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first-line venetoclax plus azacitidine treatment and in participants with newly diagnosed unfit AML presenting with high-risk clinical features (CHDM201I12201)
Clinical Trial 21469
A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203)
Clinical Trial 21356
AN OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Clinical Trial ADCT-402-105
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Clinical Trial USOR 20285
A Phase 2 Trial of Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Combination with Selinexor For Patients with Newly Diagnosed Multiple Myeloma
All Clinical Trials for Mitul Gandhi, MD
Clinical Trial 22041
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 1-3a when Administered in the Outpatient Setting (M23-362)
ClinicalTrials.gov ID:
NCT05451810
ClinicalTrials.gov Link:
Clinical Trial 21287
A phase Ib/II open label dose confirmation, proof of concept study of siremadlin in combination with venetoclax plus azacitidine in unfit adult AML participants who responded sub-optimally to first-line venetoclax plus azacitidine treatment and in participants with newly diagnosed unfit AML presenting with high-risk clinical features (CHDM201I12201)
Clinical Trial 21469
A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203)
ClinicalTrials.gov ID:
NCT05144009
ClinicalTrials.gov Link:
Clinical Trial 21356
AN OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
ClinicalTrials.gov ID:
NCT05207670
ClinicalTrials.gov Link:
Clinical Trial ADCT-402-105
A Phase 1b Open-Label Study to Evaluate the Safety and Anti-Cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-Cancer Agents in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Clinical Trial USOR 20285
A Phase 2 Trial of Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Combination with Selinexor For Patients with Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov ID:
NCT04782687
ClinicalTrials.gov Link:
Clinical Trial M20-178
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis
ClinicalTrials.gov ID:
NCT04468984
ClinicalTrials.gov Link:
Clinical Trial 20346
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician’s Choice in Patients with Previously Treated Myelofibrosis
Clinical Trial SLSG18-301
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator’s Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line Salvage Therapy
ClinicalTrials.gov ID:
NCT04229979
ClinicalTrials.gov Link:
Clinical Trial 20287
A Phase Ib/II Study of APG-115 Alone or in Combination With Azacitidine in Patients with Relapsed/Refractory AML
Clinical Trial 20343
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator’s Choice of Idelalisib Plus Rituxan or Bendamustine Plus Rituxan in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
ClinicalTrials.gov ID:
NCT04666038
ClinicalTrials.gov Link:
Clinical Trial ADCT-402-311
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined with Rituximab Versus Immunochemotherapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
ClinicalTrials.gov ID:
NCT04384484
ClinicalTrials.gov Link:
Clinical Trial 20336
A Phase 3, Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma
ClinicalTrials.gov ID:
NCT04662255
ClinicalTrials.gov Link:
Clinical Trial 19062
Phase 3 Double-Blind, Active Controlled, 3-Stage Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma.
ClinicalTrials.gov ID:
NCT04224493
ClinicalTrials.gov Link:
Clinical Trial 20298
Phase 2 Study of VS-6766 (Dual RAK/MEK Inhibitor) Alone and in Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
ClinicalTrials.gov ID:
NCT04625270
ClinicalTrials.gov Link:
Clinical Trial D967JC00001
A Phase 1b/2 Multicenter, Open-Label, Dose Finding Study to Explore Safety, Efficacy, and Activity of Trastuzumab Deruxtecan (T-Dxd) in Combination with Other Anti-Cancer Agents in Patients with HER2+ Metastatic Breast Cancer
Clinical Trial 18263
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)
ClinicalTrials.gov ID:
NCT03206918
ClinicalTrials.gov Link:
Clinical Trial 19247
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)
ClinicalTrials.gov ID:
NCT03901963
ClinicalTrials.gov Link:
